

Drug Repurposing Guidebook

Building Block I451

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	Remedi
References	<ul style="list-style-type: none"> • https://drugrepurposing.org/remedi/ • https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02 • VUMC Remedi Jan2020 4444-1.pdf • https://drugrepurposing.org/enrolling/ • https://www.youtube.com/watch?v=MuuACS2hgX8 • https://www.jclinepi.com/article/S0895-4356(22)00325-0/fulltext
Description	<p>Repurposing Essential Medicines Internationally (Remedi) represents an initiative to identify new therapeutic uses for the medications included in the list of WHO’s Essential Medicines List.</p> <p>Safe and affordable medications are included in that list and selection is based on data about disease prevalence and public health relevance, previous evidence of efficacy and safety, as well as cost-effectiveness data.</p> <p>The afore-mentioned list is updated every 2 years (last update in 2021) and offers flexibility to regional authorities to use as per local priorities.</p> <p>Remedi is an interactive tool generated by international internship and collaboration among institutions and centres.</p>

ITEM	DESCRIPTION
	<p>Remedi provides an overview of the established use(s) of agents in the essential medications list, as well as an overview of their additional suggested uses.</p> <p>The rationale is to expand the utility of existing medications and reveal new uses to benefit populations, especially in low- and middle-income countries and for rare and serious diseases.</p> <p>This can also enhance and facilitate drug research but also permit safe clinical decisions and treatment choices in exceptional situations.</p>
Category	Supporting tools
Geographical scope	International
Availability	<p>Availability to all clinicians working with patients with rare or serious diseases, especially in settings with limited resources</p> <p>Availability to applicants and stakeholders involved in the process of drug repurposing, especially in the early stages.</p>
Scope of use	<p>This is an already existing resource.</p> <p>The scope with this building block is:</p> <ul style="list-style-type: none"> • To increase its accessibility and promote its wider application. • To make drug developers and healthcare professionals aware of this tool • To familiarize drug developers and healthcare professionals with its use and format.
Stakeholders involved	<p>Both from clinical and research field:</p> <ul style="list-style-type: none"> • Basic scientists • Bioinformaticians • Clinical researchers (investigators)

ITEM	DESCRIPTION
	<ul style="list-style-type: none"> • Healthcare workers • Rare diseases experts • Research pharmacists • Clinical pharmacologists • Pharmacovigilance officers • Regional/local regulatory authorities
Enablers/ Requirements	<ul style="list-style-type: none"> • A basic understanding of the underlying biology, pathophysiology of and disease mechanisms • Training of all the involved stakeholders about its use
Output	<p>The output of this block will be of both research and clinical utility.</p> <ul style="list-style-type: none"> • To produce a tool which will allow drug developers (stakeholders) to have easy access to safe and sound information about medications currently in use and to identify agents which could be re-purposed. • To produce a tool which can be used by healthcare professionals in order to guide their decisions when dealing with patients with rare or serious diseases.
Best time to apply and time window	<p><u>Clinical use</u>: In all stages of clinical care, especially in areas with inadequate resources or in cases of patients with complex conditions.</p> <p><u>Research use</u>: By definition, being familiar with the list of all available medications is applied in the early stages of the process of drug-repurposing, as the already available medications represent the “source” of repurposed drugs.</p>
Expert tips	<ul style="list-style-type: none"> • To bear in mind that this list is not exhaustive and resources from additional organizations can also be considered. • To consider the special circumstances (e.g. regulatory issues) in each geographic area.

